Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 CYSLTR1 [1] Neuroactive ligand-receptor interaction D00529 Montelukast [8] 6, 13, 46, 61, 63, 85, 98, 228
2 CYSLTR1 [1] Neuroactive ligand-receptor interaction D01385 Ibudilast [2] 2, 13
3 CYSLTR1 [1] Neuroactive ligand-receptor interaction D06659 Tipelukast [1] 85
4 CYSLTR1 [1] Neuroactive ligand-receptor interaction D08229 Montelukast [8] 6, 13, 46, 61, 63, 85, 98, 228
5 HRH3 [1] Neuroactive ligand-receptor interaction D08040 Histamine [1] 13
6 HRH3 [1] Neuroactive ligand-receptor interaction D09870 Bavisant [1] 6
7 HRH3 [1] Neuroactive ligand-receptor interaction D10749 Pitolisant [3] 6, 113, 193
8 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00113 Atropine [2] 2, 299
9 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00138 Scopolamine [1] 2
10 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00270 Chlorpromazine [1] 254
11 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [3] 6, 13, 19
12 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
13 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00481 Propantheline [1] 26
14 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00722 Oxybutynin [3] 6, 13, 53
15 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00765 Rocuronium [1] 296
16 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00787 Trihexyphenidyl [2] 5, 6
17 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00789 Chlorpromazine [1] 254
18 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D01000 Bethanechol [1] 98
19 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D01077 Atropine [2] 2, 299
20 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D02069 Atropine [2] 2, 299
21 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D02212 Ipratropium [2] 6, 86
22 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D03011 Atropine [2] 2, 299
23 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D03274 Chlorpromazine [1] 254
24 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D03814 Atropine [2] 2, 299
25 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D04034 Chlorpromazine [1] 254
26 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D08441 Propiverine [1] 226
27 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
28 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D11383 Blarcamesine [1] 156
29 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00113 Atropine [2] 2, 299
30 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00138 Scopolamine [1] 2
31 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00270 Chlorpromazine [1] 254
32 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00397 Tropicamide [3] 6, 13, 19
33 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00465 Oxybutynin [3] 6, 13, 53
34 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00481 Propantheline [1] 26
35 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00525 Pilocarpine [3] 6, 53, 299
36 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00722 Oxybutynin [3] 6, 13, 53
37 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00765 Rocuronium [1] 296
38 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00787 Trihexyphenidyl [2] 5, 6
39 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00789 Chlorpromazine [1] 254
40 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D01000 Bethanechol [1] 98
41 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D01077 Atropine [2] 2, 299
42 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D02069 Atropine [2] 2, 299
43 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D02200 Pilocarpine [3] 6, 53, 299
44 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D02212 Ipratropium [2] 6, 86
45 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D03011 Atropine [2] 2, 299
46 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D03274 Chlorpromazine [1] 254
47 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D03814 Atropine [2] 2, 299
48 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D04034 Chlorpromazine [1] 254
49 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D05478 Pilocarpine [3] 6, 53, 299
50 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D07226 Fesoterodine [1] 6
51 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D08441 Propiverine [1] 226
52 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D08638 Trihexyphenidyl [2] 5, 6
53 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D11383 Blarcamesine [1] 156
54 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00113 Atropine [2] 2, 299
55 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00138 Scopolamine [1] 2
56 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00270 Chlorpromazine [1] 254
57 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [3] 6, 13, 19
58 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
59 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00481 Propantheline [1] 26
60 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00525 Pilocarpine [3] 6, 53, 299
61 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00646 Tolterodine [2] 17, 53
62 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00661 Cevimeline [1] 53
63 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00722 Oxybutynin [3] 6, 13, 53
64 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00765 Rocuronium [1] 296
65 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00787 Trihexyphenidyl [2] 5, 6
66 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00789 Chlorpromazine [1] 254
67 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D01000 Bethanechol [1] 98
68 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D01077 Atropine [2] 2, 299
69 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D01148 Tolterodine [2] 17, 53
70 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D01269 Solifenacin [3] 6, 13, 53
71 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D01699 Darifenacin [2] 6, 13
72 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D02069 Atropine [2] 2, 299
73 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D02200 Pilocarpine [3] 6, 53, 299
74 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D02212 Ipratropium [2] 6, 86
75 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D03011 Atropine [2] 2, 299
76 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D03274 Chlorpromazine [1] 254
77 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D03654 Darifenacin [2] 6, 13
78 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D03814 Atropine [2] 2, 299
79 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D04034 Chlorpromazine [1] 254
80 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D05478 Pilocarpine [3] 6, 53, 299
81 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D07226 Fesoterodine [1] 6
82 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D07667 Cevimeline [1] 53
83 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D08441 Propiverine [1] 226
84 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D08522 Solifenacin [3] 6, 13, 53
85 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
86 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D11383 Blarcamesine [1] 156
87 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00113 Atropine [2] 2, 299
88 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00138 Scopolamine [1] 2
89 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00270 Chlorpromazine [1] 254
90 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00397 Tropicamide [3] 6, 13, 19
91 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00465 Oxybutynin [3] 6, 13, 53
92 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00481 Propantheline [1] 26
93 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00722 Oxybutynin [3] 6, 13, 53
94 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00765 Rocuronium [1] 296
95 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00787 Trihexyphenidyl [2] 5, 6
96 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00789 Chlorpromazine [1] 254
97 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D01000 Bethanechol [1] 98
98 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D01077 Atropine [2] 2, 299
99 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D02069 Atropine [2] 2, 299
100 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D02212 Ipratropium [2] 6, 86
101 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D03011 Atropine [2] 2, 299
102 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D03274 Chlorpromazine [1] 254
103 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D03814 Atropine [2] 2, 299
104 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D04034 Chlorpromazine [1] 254
105 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D08441 Propiverine [1] 226
106 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D08638 Trihexyphenidyl [2] 5, 6
107 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D11383 Blarcamesine [1] 156
108 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00113 Atropine [2] 2, 299
109 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00138 Scopolamine [1] 2
110 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00270 Chlorpromazine [1] 254
111 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [3] 6, 13, 19
112 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
113 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00481 Propantheline [1] 26
114 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00722 Oxybutynin [3] 6, 13, 53
115 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00765 Rocuronium [1] 296
116 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00787 Trihexyphenidyl [2] 5, 6
117 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00789 Chlorpromazine [1] 254
118 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D01000 Bethanechol [1] 98
119 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D01077 Atropine [2] 2, 299
120 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D02069 Atropine [2] 2, 299
121 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D02212 Ipratropium [2] 6, 86
122 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D03011 Atropine [2] 2, 299
123 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D03274 Chlorpromazine [1] 254
124 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D03814 Atropine [2] 2, 299
125 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D04034 Chlorpromazine [1] 254
126 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D08441 Propiverine [1] 226
127 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
128 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D11383 Blarcamesine [1] 156
129 CHRNA1 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
130 CHRNA1 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
131 CHRNA1 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
132 CHRNA2 [1] Neuroactive ligand-receptor interaction D00765 Rocuronium [1] 296
133 CHRNA2 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
134 CHRNA2 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
135 CHRNA2 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
136 CHRNA3 [1] Neuroactive ligand-receptor interaction D00765 Rocuronium [1] 296
137 CHRNA3 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
138 CHRNA3 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
139 CHRNA3 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
140 CHRNA4 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D00765 Rocuronium [1] 296
141 CHRNA4 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D03365 Nicotine [3] 6, 13, 84
142 CHRNA4 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D05156 Nicotine [3] 6, 13, 84
143 CHRNA4 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D05157 Nicotine [3] 6, 13, 84
144 CHRNA4 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D08669 Varenicline [2] 6, 18
145 CHRNA5 [1] Neuroactive ligand-receptor interaction D00765 Rocuronium [1] 296
146 CHRNA5 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
147 CHRNA5 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
148 CHRNA5 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
149 CHRNA7 [3] Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00765 Rocuronium [1] 296
150 CHRNA7 [3] Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03365 Nicotine [3] 6, 13, 84
151 CHRNA7 [3] Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D05156 Nicotine [3] 6, 13, 84
152 CHRNA7 [3] Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D05157 Nicotine [3] 6, 13, 84
153 CHRNB1 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
154 CHRNB1 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
155 CHRNB1 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
156 CHRNB2 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D00765 Rocuronium [1] 296
157 CHRNB2 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D03365 Nicotine [3] 6, 13, 84
158 CHRNB2 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D05156 Nicotine [3] 6, 13, 84
159 CHRNB2 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D05157 Nicotine [3] 6, 13, 84
160 CHRNB2 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D08669 Varenicline [2] 6, 18
161 CHRNB3 [1] Neuroactive ligand-receptor interaction D00765 Rocuronium [1] 296
162 CHRNB3 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
163 CHRNB3 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
164 CHRNB3 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
165 CHRNB4 [1] Neuroactive ligand-receptor interaction D00765 Rocuronium [1] 296
166 CHRNB4 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
167 CHRNB4 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
168 CHRNB4 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
169 CHRND [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
170 CHRND [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
171 CHRND [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
172 CHRNE [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
173 CHRNE [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
174 CHRNE [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
175 CHRNG [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
176 CHRNG [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
177 CHRNG [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
178 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D00306 Dronabinol [8] 2, 8, 13, 36, 46, 96, 271, 298
179 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D05099 Nabilone [2] 6, 13
180 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D05731 Rimonabant [1] 193
181 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D10915 Cannabidiol [19] 2, 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
182 CNR2 [1] Neuroactive ligand-receptor interaction D00306 Dronabinol [8] 2, 8, 13, 36, 46, 96, 271, 298
183 CNR2 [1] Neuroactive ligand-receptor interaction D05099 Nabilone [2] 6, 13
184 CNR2 [1] Neuroactive ligand-receptor interaction D10915 Cannabidiol [19] 2, 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
185 CNR2 [1] Neuroactive ligand-receptor interaction D11312 Ajulemic acid [3] 50, 51, 299
186 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D00045 Adenosine [3] 13, 58, 65
187 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D00227 Aminophylline [1] 63
188 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D00371 Theophylline [2] 236, 299
189 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
190 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
191 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D01712 Theophylline [2] 236, 299
192 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D02017 Theophylline [2] 236, 299
193 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D02769 Adenosine phosphate [1] 46
194 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D05429 Aminophylline [1] 63
195 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D06103 Theophylline [2] 236, 299
196 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D06104 Theophylline [2] 236, 299
197 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D00045 Adenosine [3] 13, 58, 65
198 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
199 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
200 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D02017 Theophylline [2] 236, 299
201 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D02769 Adenosine phosphate [1] 46
202 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D04641 Istradefylline [1] 6
203 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D05711 Regadenoson [1] 58
204 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D09717 Preladenant [1] 6
205 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D10174 Tozadenant [1] 6
206 ADORA2B [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00045 Adenosine [3] 13, 58, 65
207 ADORA2B [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00227 Aminophylline [1] 63
208 ADORA2B [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00371 Theophylline [2] 236, 299
209 ADORA2B [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D01712 Theophylline [2] 236, 299
210 ADORA2B [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D02769 Adenosine phosphate [1] 46
211 ADORA2B [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D05429 Aminophylline [1] 63
212 ADORA2B [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06103 Theophylline [2] 236, 299
213 ADORA2B [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06104 Theophylline [2] 236, 299
214 CRHR1 [1] Neuroactive ligand-receptor interaction D03592 Corticorelin ovine triflutate [1] 75
215 CRHR1 [1] Neuroactive ligand-receptor interaction D03905 Corticorelin [2] 75, 205
216 CRHR2 [1] Neuroactive ligand-receptor interaction D03592 Corticorelin ovine triflutate [1] 75
217 CRHR2 [1] Neuroactive ligand-receptor interaction D03905 Corticorelin [2] 75, 205
218 ADORA3 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00045 Adenosine [3] 13, 58, 65
219 ADORA3 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02769 Adenosine phosphate [1] 46
220 ADORA3 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10971 Piclidenoson [1] 46
221 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [1] 22
222 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
223 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
224 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
225 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
226 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine [1] 17
227 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine [1] 22
228 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin [2] 57, 67
229 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
230 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone [2] 28, 127
231 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine [3] 118, 280, 288
232 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
233 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
234 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
235 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
236 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
237 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
238 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
239 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
240 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine [1] 22
241 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine [1] 17
242 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine [1] 17
243 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
244 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
245 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil [1] 85
246 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [3] 118, 280, 288
247 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
248 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
249 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
250 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
251 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [1] 22
252 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
253 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
254 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
255 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
256 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine [1] 17
257 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine [1] 22
258 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin [2] 57, 67
259 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
260 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone [2] 28, 127
261 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine [3] 118, 280, 288
262 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
263 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
264 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
265 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
266 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
267 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
268 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
269 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
270 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine [1] 22
271 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine [1] 17
272 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine [1] 17
273 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
274 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
275 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil [1] 85
276 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [3] 118, 280, 288
277 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
278 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
279 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
280 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
281 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [1] 22
282 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
283 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
284 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
285 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
286 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine [1] 17
287 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine [1] 22
288 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin [2] 57, 67
289 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
290 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone [2] 28, 127
291 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine [3] 118, 280, 288
292 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
293 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
294 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
295 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01692 Alfuzosin [1] 13
296 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01965 Silodosin [2] 6, 13
297 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
298 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
299 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
300 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
301 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
302 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine [1] 22
303 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine [1] 17
304 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine [1] 17
305 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
306 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07124 Alfuzosin [1] 13
307 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
308 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil [1] 85
309 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [3] 118, 280, 288
310 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
311 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
312 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
313 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
314 ADRA2A [1] Neuroactive ligand-receptor interaction D00076 Norepinephrine [1] 22
315 ADRA2A [1] Neuroactive ligand-receptor interaction D00095 Epinephrine [3] 46, 70, 96
316 ADRA2A [1] Neuroactive ligand-receptor interaction D00124 Ephedrine [1] 11
317 ADRA2A [1] Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
318 ADRA2A [1] Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
319 ADRA2A [1] Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
320 ADRA2A [1] Neuroactive ligand-receptor interaction D00405 Methyldopa [1] 323
321 ADRA2A [1] Neuroactive ligand-receptor interaction D00485 Pseudoephedrine [1] 17
322 ADRA2A [1] Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
323 ADRA2A [1] Neuroactive ligand-receptor interaction D00560 Pimozide [1] 2
324 ADRA2A [1] Neuroactive ligand-receptor interaction D00604 Clonidine [4] 6, 65, 70, 78
325 ADRA2A [1] Neuroactive ligand-receptor interaction D00606 Guanfacine [1] 193
326 ADRA2A [1] Neuroactive ligand-receptor interaction D00680 Methylergometrine [3] 118, 280, 288
327 ADRA2A [1] Neuroactive ligand-receptor interaction D00776 Tizanidine [1] 13
328 ADRA2A [1] Neuroactive ligand-receptor interaction D00789 Chlorpromazine [1] 254
329 ADRA2A [1] Neuroactive ligand-receptor interaction D00996 Epinephrine [3] 46, 70, 96
330 ADRA2A [1] Neuroactive ligand-receptor interaction D01008 Apraclonidine [1] 11
331 ADRA2A [1] Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
332 ADRA2A [1] Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
333 ADRA2A [1] Neuroactive ligand-receptor interaction D02076 Brimonidine [2] 13, 90
334 ADRA2A [1] Neuroactive ligand-receptor interaction D02149 Epinephrine [3] 46, 70, 96
335 ADRA2A [1] Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate [2] 6, 206
336 ADRA2A [1] Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
337 ADRA2A [1] Neuroactive ligand-receptor interaction D03274 Chlorpromazine [1] 254
338 ADRA2A [1] Neuroactive ligand-receptor interaction D04034 Chlorpromazine [1] 254
339 ADRA2A [1] Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
340 ADRA2A [1] Neuroactive ligand-receptor interaction D05206 Norepinephrine [1] 22
341 ADRA2A [1] Neuroactive ligand-receptor interaction D05648 Pseudoephedrine [1] 17
342 ADRA2A [1] Neuroactive ligand-receptor interaction D05649 Pseudoephedrine [1] 17
343 ADRA2A [1] Neuroactive ligand-receptor interaction D07461 Apraclonidine [1] 11
344 ADRA2A [1] Neuroactive ligand-receptor interaction D07540 Brimonidine [2] 13, 90
345 ADRA2A [1] Neuroactive ligand-receptor interaction D08031 Guanfacine [1] 193
346 ADRA2A [1] Neuroactive ligand-receptor interaction D08205 Methyldopa [1] 323
347 ADRA2A [1] Neuroactive ligand-receptor interaction D08207 Methylergometrine [3] 118, 280, 288
348 ADRA2A [1] Neuroactive ligand-receptor interaction D08449 Pseudoephedrine [1] 17
349 ADRA2A [1] Neuroactive ligand-receptor interaction D08482 Rilmenidine [1] 8
350 ADRA2A [1] Neuroactive ligand-receptor interaction D08611 Tizanidine [1] 13
351 ADRA2A [1] Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
352 ADRA2B [1] Neuroactive ligand-receptor interaction D00076 Norepinephrine [1] 22
353 ADRA2B [1] Neuroactive ligand-receptor interaction D00095 Epinephrine [3] 46, 70, 96
354 ADRA2B [1] Neuroactive ligand-receptor interaction D00124 Ephedrine [1] 11
355 ADRA2B [1] Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
356 ADRA2B [1] Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
357 ADRA2B [1] Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
358 ADRA2B [1] Neuroactive ligand-receptor interaction D00405 Methyldopa [1] 323
359 ADRA2B [1] Neuroactive ligand-receptor interaction D00485 Pseudoephedrine [1] 17
360 ADRA2B [1] Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
361 ADRA2B [1] Neuroactive ligand-receptor interaction D00604 Clonidine [4] 6, 65, 70, 78
362 ADRA2B [1] Neuroactive ligand-receptor interaction D00680 Methylergometrine [3] 118, 280, 288
363 ADRA2B [1] Neuroactive ligand-receptor interaction D00776 Tizanidine [1] 13
364 ADRA2B [1] Neuroactive ligand-receptor interaction D00789 Chlorpromazine [1] 254
365 ADRA2B [1] Neuroactive ligand-receptor interaction D00996 Epinephrine [3] 46, 70, 96
366 ADRA2B [1] Neuroactive ligand-receptor interaction D01008 Apraclonidine [1] 11
367 ADRA2B [1] Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
368 ADRA2B [1] Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
369 ADRA2B [1] Neuroactive ligand-receptor interaction D02076 Brimonidine [2] 13, 90
370 ADRA2B [1] Neuroactive ligand-receptor interaction D02149 Epinephrine [3] 46, 70, 96
371 ADRA2B [1] Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate [2] 6, 206
372 ADRA2B [1] Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
373 ADRA2B [1] Neuroactive ligand-receptor interaction D03274 Chlorpromazine [1] 254
374 ADRA2B [1] Neuroactive ligand-receptor interaction D04034 Chlorpromazine [1] 254
375 ADRA2B [1] Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
376 ADRA2B [1] Neuroactive ligand-receptor interaction D05206 Norepinephrine [1] 22
377 ADRA2B [1] Neuroactive ligand-receptor interaction D05648 Pseudoephedrine [1] 17
378 ADRA2B [1] Neuroactive ligand-receptor interaction D05649 Pseudoephedrine [1] 17
379 ADRA2B [1] Neuroactive ligand-receptor interaction D07461 Apraclonidine [1] 11
380 ADRA2B [1] Neuroactive ligand-receptor interaction D07540 Brimonidine [2] 13, 90
381 ADRA2B [1] Neuroactive ligand-receptor interaction D08205 Methyldopa [1] 323
382 ADRA2B [1] Neuroactive ligand-receptor interaction D08207 Methylergometrine [3] 118, 280, 288
383 ADRA2B [1] Neuroactive ligand-receptor interaction D08449 Pseudoephedrine [1] 17
384 ADRA2B [1] Neuroactive ligand-receptor interaction D08482 Rilmenidine [1] 8
385 ADRA2B [1] Neuroactive ligand-receptor interaction D08611 Tizanidine [1] 13
386 ADRA2B [1] Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
387 ADRA2C [1] Neuroactive ligand-receptor interaction D00076 Norepinephrine [1] 22
388 ADRA2C [1] Neuroactive ligand-receptor interaction D00095 Epinephrine [3] 46, 70, 96
389 ADRA2C [1] Neuroactive ligand-receptor interaction D00124 Ephedrine [1] 11
390 ADRA2C [1] Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
391 ADRA2C [1] Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
392 ADRA2C [1] Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
393 ADRA2C [1] Neuroactive ligand-receptor interaction D00405 Methyldopa [1] 323
394 ADRA2C [1] Neuroactive ligand-receptor interaction D00485 Pseudoephedrine [1] 17
395 ADRA2C [1] Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
396 ADRA2C [1] Neuroactive ligand-receptor interaction D00604 Clonidine [4] 6, 65, 70, 78
397 ADRA2C [1] Neuroactive ligand-receptor interaction D00680 Methylergometrine [3] 118, 280, 288
398 ADRA2C [1] Neuroactive ligand-receptor interaction D00776 Tizanidine [1] 13
399 ADRA2C [1] Neuroactive ligand-receptor interaction D00789 Chlorpromazine [1] 254
400 ADRA2C [1] Neuroactive ligand-receptor interaction D00996 Epinephrine [3] 46, 70, 96
401 ADRA2C [1] Neuroactive ligand-receptor interaction D01008 Apraclonidine [1] 11
402 ADRA2C [1] Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
403 ADRA2C [1] Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
404 ADRA2C [1] Neuroactive ligand-receptor interaction D02076 Brimonidine [2] 13, 90
405 ADRA2C [1] Neuroactive ligand-receptor interaction D02149 Epinephrine [3] 46, 70, 96
406 ADRA2C [1] Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate [2] 6, 206
407 ADRA2C [1] Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
408 ADRA2C [1] Neuroactive ligand-receptor interaction D03274 Chlorpromazine [1] 254
409 ADRA2C [1] Neuroactive ligand-receptor interaction D04034 Chlorpromazine [1] 254
410 ADRA2C [1] Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
411 ADRA2C [1] Neuroactive ligand-receptor interaction D05206 Norepinephrine [1] 22
412 ADRA2C [1] Neuroactive ligand-receptor interaction D05648 Pseudoephedrine [1] 17
413 ADRA2C [1] Neuroactive ligand-receptor interaction D05649 Pseudoephedrine [1] 17
414 ADRA2C [1] Neuroactive ligand-receptor interaction D07461 Apraclonidine [1] 11
415 ADRA2C [1] Neuroactive ligand-receptor interaction D07540 Brimonidine [2] 13, 90
416 ADRA2C [1] Neuroactive ligand-receptor interaction D08205 Methyldopa [1] 323
417 ADRA2C [1] Neuroactive ligand-receptor interaction D08207 Methylergometrine [3] 118, 280, 288
418 ADRA2C [1] Neuroactive ligand-receptor interaction D08449 Pseudoephedrine [1] 17
419 ADRA2C [1] Neuroactive ligand-receptor interaction D08482 Rilmenidine [1] 8
420 ADRA2C [1] Neuroactive ligand-receptor interaction D08611 Tizanidine [1] 13
421 ADRA2C [1] Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
422 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00076 Norepinephrine [1] 22
423 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
424 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00124 Ephedrine [1] 11
425 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00235 Atenolol [1] 167
426 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
427 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00378 Timolol [2] 157, 227
428 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00432 Nadolol [1] 6
429 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
430 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00485 Pseudoephedrine [1] 17
431 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00601 Metoprolol [6] 17, 57, 58, 113, 193, 226
432 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00603 Timolol [2] 157, 227
433 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00632 Dobutamine [3] 57, 58, 215
434 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00634 Bisoprolol [3] 67, 86, 113
435 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00636 Amiodarone [2] 28, 127
436 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00644 Esmolol [1] 58
437 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
438 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
439 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
440 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02342 Bisoprolol [3] 67, 86, 113
441 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02349 Dipivefrin [1] 6
442 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02358 Metoprolol [6] 17, 57, 58, 113, 193, 226
443 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02910 Amiodarone [2] 28, 127
444 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
445 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D03879 Dobutamine [3] 57, 58, 215
446 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D03880 Dobutamine [3] 57, 58, 215
447 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D03881 Dobutamine [3] 57, 58, 215
448 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05011 Metoprolol [6] 17, 57, 58, 113, 193, 226
449 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05127 Nebivolol [4] 17, 85, 113, 167
450 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05206 Norepinephrine [1] 22
451 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05648 Pseudoephedrine [1] 17
452 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05649 Pseudoephedrine [1] 17
453 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D07660 Celiprolol [1] 168
454 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D07916 Esmolol [1] 58
455 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
456 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08449 Pseudoephedrine [1] 17
457 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08600 Timolol [2] 157, 227
458 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00076 Norepinephrine [1] 22
459 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
460 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00124 Ephedrine [1] 11
461 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
462 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00378 Timolol [2] 157, 227
463 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00432 Nadolol [1] 6
464 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
465 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00485 Pseudoephedrine [1] 17
466 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00603 Timolol [2] 157, 227
467 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00687 Salmeterol [1] 299
468 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00688 Terbutaline [1] 118
469 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
470 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
471 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D01373 Formoterol [3] 85, 228, 299
472 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02147 Salbutamol [14] 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299
473 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
474 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02151 Tulobuterol [1] 6
475 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02349 Dipivefrin [1] 6
476 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
477 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05206 Norepinephrine [1] 22
478 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05277 Formoterol [3] 85, 228, 299
479 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05648 Pseudoephedrine [1] 17
480 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05649 Pseudoephedrine [1] 17
481 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05792 Salmeterol [1] 299
482 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D07713 Clenbuterol [5] 1, 2, 6, 13, 256
483 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D07990 Formoterol [3] 85, 228, 299
484 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08092 Isoxsuprine [1] 13
485 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08124 Levosalbutamol [1] 49
486 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
487 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08449 Pseudoephedrine [1] 17
488 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08570 Terbutaline [1] 118
489 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08600 Timolol [2] 157, 227
490 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00076 Norepinephrine [1] 22
491 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
492 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00124 Ephedrine [1] 11
493 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
494 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00485 Pseudoephedrine [1] 17
495 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
496 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
497 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
498 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02349 Dipivefrin [1] 6
499 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05206 Norepinephrine [1] 22
500 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05648 Pseudoephedrine [1] 17
501 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05649 Pseudoephedrine [1] 17
502 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
503 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08449 Pseudoephedrine [1] 17
504 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D09535 Mirabegron [4] 6, 13, 53, 226
505 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
506 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D00502 Pergolide [1] 6
507 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D00633 Dopamine [4] 6, 7, 74, 299
508 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D01044 Flupentixol [1] 97
509 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D02004 Apomorphine [3] 5, 6, 7
510 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D07460 Apomorphine [3] 5, 6, 7
511 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D07870 Dopamine [4] 6, 7, 74, 299
512 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D08339 Pergolide [1] 6
513 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D09886 Dexpramipexole [1] 2
514 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D11431 Tavapadon [1] 6
515 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D11839 Foslevodopa [1] 6
516 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
517 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00136 Haloperidol [1] 8
518 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00270 Chlorpromazine [1] 254
519 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00426 Risperidone [5] 8, 156, 179, 187, 206
520 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00454 Olanzapine [2] 2, 8
521 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00458 Quetiapine [2] 6, 13
522 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00502 Pergolide [1] 6
523 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00559 Pramipexole [3] 2, 6, 20
524 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00560 Pimozide [1] 2
525 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00633 Dopamine [4] 6, 7, 74, 299
526 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00702 Buspirone [3] 6, 51, 179
527 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00726 Metoclopramide [1] 51
528 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00780 Bromocriptine [2] 6, 74
529 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00784 Ropinirole [4] 2, 6, 74, 309
530 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00789 Chlorpromazine [1] 254
531 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00799 Trifluoperazine [2] 283, 284
532 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00987 Cabergoline [3] 6, 74, 75
533 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01044 Flupentixol [1] 97
534 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01164 Aripiprazole [2] 6, 206
535 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01226 Sulpiride [5] 2, 6, 17, 46, 70
536 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01348 Terguride [2] 51, 86
537 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01448 Trifluoperazine [2] 283, 284
538 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01462 Lisuride [2] 6, 86
539 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01745 Domperidone [5] 6, 13, 17, 51, 230
540 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01898 Haloperidol [1] 8
541 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D02004 Apomorphine [3] 5, 6, 7
542 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D02213 Metoclopramide [1] 51
543 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D03165 Bromocriptine [2] 6, 74
544 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D03274 Chlorpromazine [1] 254
545 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D04034 Chlorpromazine [1] 254
546 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D05008 Metoclopramide [1] 51
547 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D05575 Pramipexole [3] 2, 6, 20
548 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D05768 Rotigotine [2] 6, 127
549 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D06623 Olanzapine [2] 2, 8
550 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D07305 Piribedil [1] 6
551 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D07309 Melperone [1] 6
552 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D07460 Apomorphine [3] 5, 6, 7
553 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D07593 Buspirone [3] 6, 51, 179
554 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D07868 Domperidone [5] 6, 13, 17, 51, 230
555 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D07870 Dopamine [4] 6, 7, 74, 299
556 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D08132 Lisuride [2] 6, 86
557 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D08339 Pergolide [1] 6
558 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D08456 Quetiapine [2] 6, 13
559 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D08489 Ropinirole [4] 2, 6, 74, 309
560 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D08549 Sulpiride [5] 2, 6, 17, 46, 70
561 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D08590 Tiapride [1] 8
562 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D08636 Trifluoperazine [2] 283, 284
563 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D09397 Pardoprunox [1] 6
564 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D09886 Dexpramipexole [1] 2
565 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D09953 Pridopidine [3] 2, 6, 8
566 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D09997 Cariprazine [1] 21
567 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D11839 Foslevodopa [1] 6
568 DRD3 [1] Neuroactive ligand-receptor interaction D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
569 DRD3 [1] Neuroactive ligand-receptor interaction D00454 Olanzapine [2] 2, 8
570 DRD3 [1] Neuroactive ligand-receptor interaction D00559 Pramipexole [3] 2, 6, 20
571 DRD3 [1] Neuroactive ligand-receptor interaction D00633 Dopamine [4] 6, 7, 74, 299
572 DRD3 [1] Neuroactive ligand-receptor interaction D00784 Ropinirole [4] 2, 6, 74, 309
573 DRD3 [1] Neuroactive ligand-receptor interaction D01164 Aripiprazole [2] 6, 206
574 DRD3 [1] Neuroactive ligand-receptor interaction D01462 Lisuride [2] 6, 86
575 DRD3 [1] Neuroactive ligand-receptor interaction D05575 Pramipexole [3] 2, 6, 20
576 DRD3 [1] Neuroactive ligand-receptor interaction D06623 Olanzapine [2] 2, 8
577 DRD3 [1] Neuroactive ligand-receptor interaction D07305 Piribedil [1] 6
578 DRD3 [1] Neuroactive ligand-receptor interaction D07870 Dopamine [4] 6, 7, 74, 299
579 DRD3 [1] Neuroactive ligand-receptor interaction D08132 Lisuride [2] 6, 86
580 DRD3 [1] Neuroactive ligand-receptor interaction D08489 Ropinirole [4] 2, 6, 74, 309
581 DRD3 [1] Neuroactive ligand-receptor interaction D09397 Pardoprunox [1] 6
582 DRD3 [1] Neuroactive ligand-receptor interaction D09886 Dexpramipexole [1] 2
583 DRD3 [1] Neuroactive ligand-receptor interaction D11839 Foslevodopa [1] 6
584 DRD4 [1] Neuroactive ligand-receptor interaction D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
585 DRD4 [1] Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
586 DRD4 [1] Neuroactive ligand-receptor interaction D00454 Olanzapine [2] 2, 8
587 DRD4 [1] Neuroactive ligand-receptor interaction D00559 Pramipexole [3] 2, 6, 20
588 DRD4 [1] Neuroactive ligand-receptor interaction D00633 Dopamine [4] 6, 7, 74, 299
589 DRD4 [1] Neuroactive ligand-receptor interaction D00784 Ropinirole [4] 2, 6, 74, 309
590 DRD4 [1] Neuroactive ligand-receptor interaction D01462 Lisuride [2] 6, 86
591 DRD4 [1] Neuroactive ligand-receptor interaction D05575 Pramipexole [3] 2, 6, 20
592 DRD4 [1] Neuroactive ligand-receptor interaction D06623 Olanzapine [2] 2, 8
593 DRD4 [1] Neuroactive ligand-receptor interaction D07870 Dopamine [4] 6, 7, 74, 299
594 DRD4 [1] Neuroactive ligand-receptor interaction D08132 Lisuride [2] 6, 86
595 DRD4 [1] Neuroactive ligand-receptor interaction D08489 Ropinirole [4] 2, 6, 74, 309
596 DRD4 [1] Neuroactive ligand-receptor interaction D09886 Dexpramipexole [1] 2
597 DRD4 [1] Neuroactive ligand-receptor interaction D11839 Foslevodopa [1] 6
598 DRD5 [1] Neuroactive ligand-receptor interaction D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
599 DRD5 [1] Neuroactive ligand-receptor interaction D00633 Dopamine [4] 6, 7, 74, 299
600 DRD5 [1] Neuroactive ligand-receptor interaction D07870 Dopamine [4] 6, 7, 74, 299
601 DRD5 [1] Neuroactive ligand-receptor interaction D09886 Dexpramipexole [1] 2
602 DRD5 [1] Neuroactive ligand-receptor interaction D11431 Tavapadon [1] 6
603 DRD5 [1] Neuroactive ligand-receptor interaction D11839 Foslevodopa [1] 6
604 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00150 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
605 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00357 Losartan [18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
606 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00400 Valsartan [7] 57, 58, 66, 75, 218, 222, 224
607 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00522 Candesartan cilexetil [1] 67
608 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00522 Candesartan [2] 58, 67
609 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00523 Irbesartan [4] 66, 167, 168, 222
610 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00626 Candesartan cilexetil [1] 67
611 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00627 Telmisartan [2] 66, 67
612 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D02014 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
613 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D08146 Losartan [18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
614 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D11776 Sparsentan [3] 66, 218, 222
615 AGTR2 [2] Neuroactive ligand-receptor interaction, Renin-angiotensin system D00150 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
616 AGTR2 [2] Neuroactive ligand-receptor interaction, Renin-angiotensin system D02014 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
617 S1PR1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10001 Fingolimod [3] 13, 14, 156
618 S1PR1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10930 Etrasimod [3] 96, 97, 98
619 S1PR1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod [3] 13, 96, 97
620 S1PR1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11215 Ponesimod [1] 13
621 S1PR1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11283 Cenerimod [1] 49
622 S1PR1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11460 Siponimod [2] 13, 50
623 S1PR3 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10930 Etrasimod [3] 96, 97, 98
624 S1PR3 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod [3] 13, 96, 97
625 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D01227 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
626 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07077 Ambrisentan [7] 51, 84, 85, 86, 88, 210, 211
627 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07171 Sitaxentan [1] 86
628 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07538 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
629 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07741 Zibotentan [1] 51
630 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D10135 Macitentan [5] 51, 85, 86, 88, 210
631 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D11776 Sparsentan [3] 66, 218, 222
632 EDNRB [3] Neuroactive ligand-receptor interaction, Relaxin signaling pathway, Pathways in cancer D01227 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
633 EDNRB [3] Neuroactive ligand-receptor interaction, Relaxin signaling pathway, Pathways in cancer D07538 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
634 EDNRB [3] Neuroactive ligand-receptor interaction, Relaxin signaling pathway, Pathways in cancer D10135 Macitentan [5] 51, 85, 86, 88, 210
635 F2 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation, Regulation of actin cytoskeleton, Pathogenic Escherichia coli infection, Pathways in cancer D06410 Thrombomodulin Alfa [1] 85
636 F2 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation, Regulation of actin cytoskeleton, Pathogenic Escherichia coli infection, Pathways in cancer D07144 Dabigatran etexilate [1] 51
637 F2 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation, Regulation of actin cytoskeleton, Pathogenic Escherichia coli infection, Pathways in cancer D09707 Dabigatran [4] 51, 85, 91, 124
638 GABBR1 [2] Neuroactive ligand-receptor interaction, Taste transduction D00241 Baclofen [7] 2, 10, 13, 18, 65, 149, 206
639 GABBR1 [2] Neuroactive ligand-receptor interaction, Taste transduction D08861 Arbaclofen Placarbil [1] 13
640 GABBR1 [2] Neuroactive ligand-receptor interaction, Taste transduction D09791 Arbaclofen [2] 13, 206
641 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00225 Alprazolam [2] 8, 75
642 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00267 Chlordiazepoxide [1] 46
643 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00280 Clonazepam [1] 6
644 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
645 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00365 Lorazepam [2] 36, 231
646 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
647 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00548 Etomidate [1] 6
648 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
649 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
650 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00693 Chlordiazepoxide [1] 46
651 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
652 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
653 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
654 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01253 Clobazam [2] 140, 144
655 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01372 Zopiclone [1] 6
656 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01514 Etizolam [1] 46
657 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
658 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04282 Gaboxadol [2] 201, 206
659 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
660 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
661 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
662 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
663 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D11149 Brexanolone [1] 205
664 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00225 Alprazolam [2] 8, 75
665 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00267 Chlordiazepoxide [1] 46
666 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00280 Clonazepam [1] 6
667 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
668 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00365 Lorazepam [2] 36, 231
669 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
670 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
671 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
672 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00693 Chlordiazepoxide [1] 46
673 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
674 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
675 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
676 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01253 Clobazam [2] 140, 144
677 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01372 Zopiclone [1] 6
678 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01514 Etizolam [1] 46
679 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
680 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04282 Gaboxadol [2] 201, 206
681 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
682 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
683 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
684 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
685 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D11149 Brexanolone [1] 205
686 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00225 Alprazolam [2] 8, 75
687 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00267 Chlordiazepoxide [1] 46
688 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00280 Clonazepam [1] 6
689 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
690 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00365 Lorazepam [2] 36, 231
691 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
692 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
693 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
694 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00693 Chlordiazepoxide [1] 46
695 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
696 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
697 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
698 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01253 Clobazam [2] 140, 144
699 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01372 Zopiclone [1] 6
700 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01514 Etizolam [1] 46
701 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
702 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04282 Gaboxadol [2] 201, 206
703 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
704 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
705 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
706 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
707 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D11149 Brexanolone [1] 205
708 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00225 Alprazolam [2] 8, 75
709 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00267 Chlordiazepoxide [1] 46
710 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00280 Clonazepam [1] 6
711 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
712 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00365 Lorazepam [2] 36, 231
713 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
714 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
715 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
716 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00693 Chlordiazepoxide [1] 46
717 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
718 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
719 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
720 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01253 Clobazam [2] 140, 144
721 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01372 Zopiclone [1] 6
722 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01514 Etizolam [1] 46
723 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
724 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04282 Gaboxadol [2] 201, 206
725 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
726 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
727 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
728 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
729 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D11149 Brexanolone [1] 205
730 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00225 Alprazolam [2] 8, 75
731 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00267 Chlordiazepoxide [1] 46
732 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00280 Clonazepam [1] 6
733 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
734 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00365 Lorazepam [2] 36, 231
735 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
736 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
737 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
738 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00693 Chlordiazepoxide [1] 46
739 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
740 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
741 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
742 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01253 Clobazam [2] 140, 144
743 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01372 Zopiclone [1] 6
744 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01514 Etizolam [1] 46
745 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
746 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04282 Gaboxadol [2] 201, 206
747 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
748 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
749 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
750 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
751 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D11149 Brexanolone [1] 205
752 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00225 Alprazolam [2] 8, 75
753 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00267 Chlordiazepoxide [1] 46
754 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00280 Clonazepam [1] 6
755 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
756 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00365 Lorazepam [2] 36, 231
757 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
758 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
759 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
760 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00693 Chlordiazepoxide [1] 46
761 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
762 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
763 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
764 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01253 Clobazam [2] 140, 144
765 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01372 Zopiclone [1] 6
766 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01514 Etizolam [1] 46
767 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
768 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04282 Gaboxadol [2] 201, 206
769 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
770 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
771 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
772 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
773 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D11149 Brexanolone [1] 205
774 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00225 Alprazolam [2] 8, 75
775 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00267 Chlordiazepoxide [1] 46
776 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00280 Clonazepam [1] 6
777 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
778 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00365 Lorazepam [2] 36, 231
779 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
780 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
781 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
782 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00693 Chlordiazepoxide [1] 46
783 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
784 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
785 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
786 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01253 Clobazam [2] 140, 144
787 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01372 Zopiclone [1] 6
788 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01514 Etizolam [1] 46
789 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
790 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D04282 Gaboxadol [2] 201, 206
791 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
792 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
793 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
794 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
795 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D11149 Brexanolone [1] 205
796 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00225 Alprazolam [2] 8, 75
797 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00267 Chlordiazepoxide [1] 46
798 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00280 Clonazepam [1] 6
799 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
800 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00365 Lorazepam [2] 36, 231
801 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
802 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
803 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
804 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00693 Chlordiazepoxide [1] 46
805 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
806 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
807 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
808 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01253 Clobazam [2] 140, 144
809 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01372 Zopiclone [1] 6
810 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01514 Etizolam [1] 46
811 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
812 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D04282 Gaboxadol [2] 201, 206
813 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
814 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
815 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
816 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
817 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D11149 Brexanolone [1] 205
818 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00225 Alprazolam [2] 8, 75
819 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00267 Chlordiazepoxide [1] 46
820 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00280 Clonazepam [1] 6
821 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
822 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00365 Lorazepam [2] 36, 231
823 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
824 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
825 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
826 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00693 Chlordiazepoxide [1] 46
827 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
828 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
829 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
830 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01253 Clobazam [2] 140, 144
831 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01372 Zopiclone [1] 6
832 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01514 Etizolam [1] 46
833 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
834 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D04282 Gaboxadol [2] 201, 206
835 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
836 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
837 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
838 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
839 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D11149 Brexanolone [1] 205
840 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
841 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00267 Chlordiazepoxide [1] 46
842 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
843 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
844 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [2] 36, 231
845 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
846 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
847 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
848 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00693 Chlordiazepoxide [1] 46
849 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
850 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
851 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
852 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
853 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
854 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01514 Etizolam [1] 46
855 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
856 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
857 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
858 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
859 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
860 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
861 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
862 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
863 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00267 Chlordiazepoxide [1] 46
864 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
865 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
866 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [2] 36, 231
867 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
868 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
869 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
870 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00693 Chlordiazepoxide [1] 46
871 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
872 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
873 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
874 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
875 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
876 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01514 Etizolam [1] 46
877 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
878 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
879 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
880 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
881 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
882 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
883 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
884 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
885 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00267 Chlordiazepoxide [1] 46
886 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
887 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
888 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [2] 36, 231
889 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
890 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
891 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
892 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00693 Chlordiazepoxide [1] 46
893 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
894 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
895 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
896 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
897 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
898 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01514 Etizolam [1] 46
899 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
900 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
901 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
902 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
903 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
904 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
905 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
906 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
907 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00267 Chlordiazepoxide [1] 46
908 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
909 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
910 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [2] 36, 231
911 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
912 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
913 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
914 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00693 Chlordiazepoxide [1] 46
915 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
916 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
917 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
918 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
919 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
920 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01514 Etizolam [1] 46
921 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
922 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
923 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
924 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
925 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
926 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
927 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
928 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
929 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00267 Chlordiazepoxide [1] 46
930 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
931 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
932 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [2] 36, 231
933 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
934 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
935 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
936 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00693 Chlordiazepoxide [1] 46
937 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
938 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
939 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
940 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
941 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
942 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01514 Etizolam [1] 46
943 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
944 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
945 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
946 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
947 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
948 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
949 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
950 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
951 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00267 Chlordiazepoxide [1] 46
952 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
953 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
954 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [2] 36, 231
955 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
956 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
957 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
958 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00693 Chlordiazepoxide [1] 46
959 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
960 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
961 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
962 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
963 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
964 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01514 Etizolam [1] 46
965 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
966 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
967 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
968 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
969 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
970 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
971 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
972 GCGR [1] Neuroactive ligand-receptor interaction D00116 Glucagon [1] 78
973 GCGR [1] Neuroactive ligand-receptor interaction D02118 Glucagon [1] 78
974 GHR [2] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway D02691 Somatotropin [23] 2, 3, 13, 19, 46, 65, 74, 75, 76, 78, 96, 107, 113, 187, 191, 193, 195, 236, 238, 265, 274, 276, 299
975 GHR [2] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway D03297 Mecasermin [6] 65, 78, 96, 168, 265, 299
976 GHR [2] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway D04870 Mecasermin [6] 65, 78, 96, 168, 265, 299
977 GHR [2] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway D05394 Pegvisomant [1] 78
978 GHR [2] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway D11193 Somavaratan [1] 78
979 GHR [2] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway D11194 Somapacitan [1] 78
980 GHR [2] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway D11486 Lonapegsomatropin [1] 78
981 GHRHR [1] Neuroactive ligand-receptor interaction D06655 Tesamorelin [2] 78, 265
982 GHRHR [1] Neuroactive ligand-receptor interaction D08523 Somatorelin [2] 13, 78
983 GHSR [1] Neuroactive ligand-receptor interaction D10563 Macimorelin [1] 78
984 GLP1R [1] Neuroactive ligand-receptor interaction D04121 Exenatide [6] 6, 17, 72, 78, 193, 233
985 GLP1R [1] Neuroactive ligand-receptor interaction D06404 Liraglutide [3] 6, 75, 193
986 GLP1R [1] Neuroactive ligand-receptor interaction D09729 Lixisenatide [1] 6
987 GLP1R [1] Neuroactive ligand-receptor interaction D09889 Dulaglutide [2] 13, 299
988 GLP1R [1] Neuroactive ligand-receptor interaction D10025 Semaglutide [1] 6
989 GNRHR [1] Neuroactive ligand-receptor interaction D00573 Goserelin [1] 1
990 GNRHR [1] Neuroactive ligand-receptor interaction D00988 Gonadorelin [1] 76
991 GNRHR [1] Neuroactive ligand-receptor interaction D00989 Leuprolide [5] 1, 2, 3, 51, 76
992 GNRHR [1] Neuroactive ligand-receptor interaction D01685 Cetrorelix [1] 46
993 GNRHR [1] Neuroactive ligand-receptor interaction D02369 Histrelin [1] 76
994 GNRHR [1] Neuroactive ligand-receptor interaction D03267 Gonadorelin [1] 76
995 GNRHR [1] Neuroactive ligand-receptor interaction D04361 Gonadorelin [1] 76
996 GNRHR [1] Neuroactive ligand-receptor interaction D04405 Goserelin [1] 1
997 GNRHR [1] Neuroactive ligand-receptor interaction D06247 Triptorelin [2] 49, 76
998 GNRHR [1] Neuroactive ligand-receptor interaction D07665 Cetrorelix [1] 46
999 GNRHR [1] Neuroactive ligand-receptor interaction D08027 Gonadorelin [1] 76
1000 GRIA1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
1001 GRIA1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1002 GRIA1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
1003 GRIA1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
1004 GRIA2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
1005 GRIA2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1006 GRIA2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
1007 GRIA2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
1008 GRIA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
1009 GRIA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1010 GRIA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D02696 Talampanel [2] 2, 6
1011 GRIA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D08964 Perampanel [3] 2, 6, 144
1012 GRIA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
1013 GRIA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1014 GRIA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
1015 GRIA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
1016 GRIK1 [1] Neuroactive ligand-receptor interaction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
1017 GRIK1 [1] Neuroactive ligand-receptor interaction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1018 GRIK2 [1] Neuroactive ligand-receptor interaction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
1019 GRIK2 [1] Neuroactive ligand-receptor interaction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1020 GRIK3 [1] Neuroactive ligand-receptor interaction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
1021 GRIK3 [1] Neuroactive ligand-receptor interaction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1022 GRIK4 [1] Neuroactive ligand-receptor interaction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
1023 GRIK4 [1] Neuroactive ligand-receptor interaction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1024 GRIK5 [1] Neuroactive ligand-receptor interaction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
1025 GRIK5 [1] Neuroactive ligand-receptor interaction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1026 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
1027 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1028 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00777 Amantadine [4] 6, 8, 13, 127
1029 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1030 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02780 Acamprosate [2] 6, 206
1031 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1032 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1033 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
1034 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07058 Acamprosate [2] 6, 206
1035 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
1036 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
1037 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
1038 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
1039 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D09917 Latrepirdine [1] 8
1040 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
1041 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1042 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00777 Amantadine [4] 6, 8, 13, 127
1043 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1044 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D02780 Acamprosate [2] 6, 206
1045 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1046 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1047 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
1048 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
1049 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
1050 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
1051 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
1052 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
1053 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
1054 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
1055 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1056 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00777 Amantadine [4] 6, 8, 13, 127
1057 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1058 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D02780 Acamprosate [2] 6, 206
1059 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1060 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1061 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
1062 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
1063 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
1064 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
1065 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
1066 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
1067 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
1068 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
1069 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1070 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00777 Amantadine [4] 6, 8, 13, 127
1071 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1072 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02780 Acamprosate [2] 6, 206
1073 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1074 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1075 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
1076 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07058 Acamprosate [2] 6, 206
1077 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
1078 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
1079 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
1080 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
1081 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D09917 Latrepirdine [1] 8
1082 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
1083 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
1084 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00777 Amantadine [4] 6, 8, 13, 127
1085 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1086 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02780 Acamprosate [2] 6, 206
1087 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1088 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
1089 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
1090 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07058 Acamprosate [2] 6, 206
1091 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
1092 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
1093 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
1094 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
1095 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D09917 Latrepirdine [1] 8
1096 NR3C1 [1] Neuroactive ligand-receptor interaction D00088 Hydrocortisone [11] 6, 41, 46, 53, 75, 78, 81, 83, 97, 98, 299
1097 NR3C1 [1] Neuroactive ligand-receptor interaction D00165 Hydrocortisone acetate [1] 97
1098 NR3C1 [1] Neuroactive ligand-receptor interaction D00244 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
1099 NR3C1 [1] Neuroactive ligand-receptor interaction D00246 Budesonide [9] 66, 93, 94, 95, 96, 97, 98, 228, 299
1100 NR3C1 [1] Neuroactive ligand-receptor interaction D00292 Dexamethasone [25] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
1101 NR3C1 [1] Neuroactive ligand-receptor interaction D00385 Triamcinolone [10] 35, 46, 56, 70, 90, 96, 107, 162, 226, 298
1102 NR3C1 [1] Neuroactive ligand-receptor interaction D00407 Methylprednisolone [48] 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
1103 NR3C1 [1] Neuroactive ligand-receptor interaction D00472 Prednisolone [43] 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
1104 NR3C1 [1] Neuroactive ligand-receptor interaction D00473 Prednisone [48] 2, 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331
1105 NR3C1 [1] Neuroactive ligand-receptor interaction D00585 Mifepristone [1] 75
1106 NR3C1 [1] Neuroactive ligand-receptor interaction D00689 Beclomethasone dipropionate [3] 85, 97, 98
1107 NR3C1 [1] Neuroactive ligand-receptor interaction D00690 Mometasone [2] 98, 162
1108 NR3C1 [1] Neuroactive ligand-receptor interaction D00690 Mometasone furoate [2] 98, 162
1109 NR3C1 [1] Neuroactive ligand-receptor interaction D00751 Methylprednisolone [48] 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
1110 NR3C1 [1] Neuroactive ligand-receptor interaction D00972 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
1111 NR3C1 [1] Neuroactive ligand-receptor interaction D00973 Cortisone acetate [1] 81
1112 NR3C1 [1] Neuroactive ligand-receptor interaction D00975 Dexamethasone [25] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
1113 NR3C1 [1] Neuroactive ligand-receptor interaction D00976 Hydrocortisone cypionate [3] 6, 81, 83
1114 NR3C1 [1] Neuroactive ligand-receptor interaction D00979 Methylprednisolone [48] 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
1115 NR3C1 [1] Neuroactive ligand-receptor interaction D00980 Prednisolone [43] 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
1116 NR3C1 [1] Neuroactive ligand-receptor interaction D00980 Prednisolone acetate [1] 222
1117 NR3C1 [1] Neuroactive ligand-receptor interaction D00981 Prednisolone [43] 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
1118 NR3C1 [1] Neuroactive ligand-receptor interaction D00982 Prednisolone [43] 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
1119 NR3C1 [1] Neuroactive ligand-receptor interaction D00983 Triamcinolone [10] 35, 46, 56, 70, 90, 96, 107, 162, 226, 298
1120 NR3C1 [1] Neuroactive ligand-receptor interaction D00984 Triamcinolone [10] 35, 46, 56, 70, 90, 96, 107, 162, 226, 298
1121 NR3C1 [1] Neuroactive ligand-receptor interaction D00985 Triamcinolone [10] 35, 46, 56, 70, 90, 96, 107, 162, 226, 298
1122 NR3C1 [1] Neuroactive ligand-receptor interaction D01239 Prednisolone [43] 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
1123 NR3C1 [1] Neuroactive ligand-receptor interaction D01272 Clobetasol propionate [2] 46, 162
1124 NR3C1 [1] Neuroactive ligand-receptor interaction D01357 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
1125 NR3C1 [1] Neuroactive ligand-receptor interaction D01402 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
1126 NR3C1 [1] Neuroactive ligand-receptor interaction D01442 Hydrocortisone succinate [3] 6, 81, 83
1127 NR3C1 [1] Neuroactive ligand-receptor interaction D01510 Dexamethasone [25] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
1128 NR3C1 [1] Neuroactive ligand-receptor interaction D01615 Dexamethasone [25] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
1129 NR3C1 [1] Neuroactive ligand-receptor interaction D01632 Dexamethasone [25] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
1130 NR3C1 [1] Neuroactive ligand-receptor interaction D01637 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
1131 NR3C1 [1] Neuroactive ligand-receptor interaction D01703 Ciclesonide [1] 84
1132 NR3C1 [1] Neuroactive ligand-receptor interaction D01708 Fluticasone propionate [2] 98, 228
1133 NR3C1 [1] Neuroactive ligand-receptor interaction D01825 Fluocinolone acetonide [1] 90
1134 NR3C1 [1] Neuroactive ligand-receptor interaction D01948 Dexamethasone [25] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
1135 NR3C1 [1] Neuroactive ligand-receptor interaction D01998 Prednisolone [43] 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
1136 NR3C1 [1] Neuroactive ligand-receptor interaction D02032 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
1137 NR3C1 [1] Neuroactive ligand-receptor interaction D02156 Prednisolone [43] 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
1138 NR3C1 [1] Neuroactive ligand-receptor interaction D02174 Dexamethasone [25] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
1139 NR3C1 [1] Neuroactive ligand-receptor interaction D02286 Betamethasone [7] 2, 28, 46, 83, 90, 96, 235
1140 NR3C1 [1] Neuroactive ligand-receptor interaction D02591 Dexamethasone [25] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
1141 NR3C1 [1] Neuroactive ligand-receptor interaction D02592 Dexamethasone [25] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
1142 NR3C1 [1] Neuroactive ligand-receptor interaction D03301 Prednisolone [43] 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
1143 NR3C1 [1] Neuroactive ligand-receptor interaction D03325 Mometasone [2] 98, 162
1144 NR3C1 [1] Neuroactive ligand-receptor interaction D03671 Deflazacort [2] 30, 113
1145 NR3C1 [1] Neuroactive ligand-receptor interaction D05000 Methylprednisolone [48] 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
1146 NR3C1 [1] Neuroactive ligand-receptor interaction D05000 Methylprednisolone hemisuccinate [7] 13, 49, 50, 51, 53, 97, 211
1147 NR3C1 [1] Neuroactive ligand-receptor interaction D05001 Methylprednisolone [48] 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
1148 NR3C1 [1] Neuroactive ligand-receptor interaction D05002 Methylprednisolone [48] 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
1149 NR3C1 [1] Neuroactive ligand-receptor interaction D06216 Triamcinolone [10] 35, 46, 56, 70, 90, 96, 107, 162, 226, 298
1150 NR3C1 [1] Neuroactive ligand-receptor interaction D07202 Halometasone [1] 162
1151 NR3C1 [1] Neuroactive ligand-receptor interaction D07495 Beclomethasone dipropionate [3] 85, 97, 98
1152 NR3C1 [1] Neuroactive ligand-receptor interaction D07715 Clobetasol propionate [2] 46, 162
1153 NR3C1 [1] Neuroactive ligand-receptor interaction D07715 Clobetasol [4] 39, 46, 51, 162
1154 NR3C1 [1] Neuroactive ligand-receptor interaction D07749 Cortisone [1] 81
1155 NR3C1 [1] Neuroactive ligand-receptor interaction D07981 Fluticasone [3] 98, 228, 299
1156 NR3C1 [1] Neuroactive ligand-receptor interaction D08227 Mometasone [2] 98, 162
1157 NR3C1 [1] Neuroactive ligand-receptor interaction D08416 Prednisone acetate [7] 35, 40, 41, 46, 49, 162, 224
1158 NR3C1 [1] Neuroactive ligand-receptor interaction D11000 Vamorolone [2] 97, 113
1159 NR3C1 [1] Neuroactive ligand-receptor interaction D11336 Relacorilant [1] 75
1160 HCRTR1 [1] Neuroactive ligand-receptor interaction D10082 Suvorexant [3] 5, 6, 13
1161 HCRTR2 [1] Neuroactive ligand-receptor interaction D10082 Suvorexant [3] 5, 6, 13
1162 HRH1 [1] Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
1163 HRH1 [1] Neuroactive ligand-receptor interaction D00300 Diphenhydramine [10] 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
1164 HRH1 [1] Neuroactive ligand-receptor interaction D00364 Loratadine [4] 13, 46, 89, 98
1165 HRH1 [1] Neuroactive ligand-receptor interaction D00454 Olanzapine [2] 2, 8
1166 HRH1 [1] Neuroactive ligand-receptor interaction D00480 Promethazine [1] 96
1167 HRH1 [1] Neuroactive ligand-receptor interaction D00494 Promethazine [1] 96
1168 HRH1 [1] Neuroactive ligand-receptor interaction D00664 Cetirizine [4] 13, 28, 35, 300
1169 HRH1 [1] Neuroactive ligand-receptor interaction D00665 Chlorpheniramine [1] 14
1170 HRH1 [1] Neuroactive ligand-receptor interaction D00666 Clemastine [1] 13
1171 HRH1 [1] Neuroactive ligand-receptor interaction D00668 Chlorpheniramine [1] 14
1172 HRH1 [1] Neuroactive ligand-receptor interaction D00669 Diphenhydramine [10] 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
1173 HRH1 [1] Neuroactive ligand-receptor interaction D00671 Fexofenadine [2] 13, 46
1174 HRH1 [1] Neuroactive ligand-receptor interaction D00789 Chlorpromazine [1] 254
1175 HRH1 [1] Neuroactive ligand-receptor interaction D00814 Doxepin [1] 6
1176 HRH1 [1] Neuroactive ligand-receptor interaction D01172 Diphenylpyraline [1] 98
1177 HRH1 [1] Neuroactive ligand-receptor interaction D01242 Promethazine [1] 96
1178 HRH1 [1] Neuroactive ligand-receptor interaction D01627 Diphenylpyraline [1] 98
1179 HRH1 [1] Neuroactive ligand-receptor interaction D02419 Diphenhydramine [10] 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
1180 HRH1 [1] Neuroactive ligand-receptor interaction D03274 Chlorpromazine [1] 254
1181 HRH1 [1] Neuroactive ligand-receptor interaction D03285 Diphenhydramine [10] 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
1182 HRH1 [1] Neuroactive ligand-receptor interaction D03290 Promethazine [1] 96
1183 HRH1 [1] Neuroactive ligand-receptor interaction D03360 Diphenhydramine [10] 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
1184 HRH1 [1] Neuroactive ligand-receptor interaction D03535 Clemastine [1] 13
1185 HRH1 [1] Neuroactive ligand-receptor interaction D03693 Desloratadine [1] 13
1186 HRH1 [1] Neuroactive ligand-receptor interaction D03854 Diphenhydramine [10] 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
1187 HRH1 [1] Neuroactive ligand-receptor interaction D04034 Chlorpromazine [1] 254
1188 HRH1 [1] Neuroactive ligand-receptor interaction D06623 Olanzapine [2] 2, 8
1189 HRH1 [1] Neuroactive ligand-receptor interaction D07398 Chlorpheniramine [1] 14
1190 HRH1 [1] Neuroactive ligand-receptor interaction D07402 Levocetirizine [1] 61
1191 HRH1 [1] Neuroactive ligand-receptor interaction D07407 Rupatadine [1] 46
1192 HRH1 [1] Neuroactive ligand-receptor interaction D07662 Cetirizine [4] 13, 28, 35, 300
1193 HRH1 [1] Neuroactive ligand-receptor interaction D07803 Chlorpheniramine [1] 14
1194 HRH1 [1] Neuroactive ligand-receptor interaction D07803 Dexchlorpheniramine [2] 13, 49
1195 HRH1 [1] Neuroactive ligand-receptor interaction D07862 Diphenylpyraline [1] 98
1196 HRH1 [1] Neuroactive ligand-receptor interaction D07875 Doxepin [1] 6
1197 HRH1 [1] Neuroactive ligand-receptor interaction D07958 Fexofenadine [2] 13, 46
1198 HRH1 [1] Neuroactive ligand-receptor interaction D08040 Histamine [1] 13
1199 HRH2 [1] Neuroactive ligand-receptor interaction D00295 Cimetidine [2] 2, 254
1200 HRH2 [1] Neuroactive ligand-receptor interaction D00318 Famotidine [7] 6, 46, 61, 86, 98, 107, 300
1201 HRH2 [1] Neuroactive ligand-receptor interaction D00422 Ranitidine [2] 13, 65
1202 HRH2 [1] Neuroactive ligand-receptor interaction D00673 Ranitidine [2] 13, 65
1203 HRH2 [1] Neuroactive ligand-receptor interaction D03503 Cimetidine [2] 2, 254
1204 HRH2 [1] Neuroactive ligand-receptor interaction D08040 Histamine [1] 13
1205 HTR1A [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D00702 Buspirone [3] 6, 51, 179
1206 HTR1A [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D01164 Aripiprazole [2] 6, 206
1207 HTR1A [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D07593 Buspirone [3] 6, 51, 179
1208 HTR1A [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D09397 Pardoprunox [1] 6
1209 HTR1A [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D09997 Cariprazine [1] 21
1210 HTR1A [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
1211 HTR1B [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D00415 Zolmitriptan [1] 6
1212 HTR1D [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D00415 Zolmitriptan [1] 6
1213 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00270 Chlorpromazine [1] 254
1214 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00274 Cisapride [1] 13
1215 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00283 Clozapine [1] 6
1216 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00426 Risperidone [5] 8, 156, 179, 187, 206
1217 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00454 Olanzapine [2] 2, 8
1218 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00458 Quetiapine [2] 6, 13
1219 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00789 Chlorpromazine [1] 254
1220 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00820 Trazodone [1] 2
1221 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D01164 Aripiprazole [2] 6, 206
1222 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D02092 Cisapride [1] 13
1223 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D03274 Chlorpromazine [1] 254
1224 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D04034 Chlorpromazine [1] 254
1225 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D06623 Olanzapine [2] 2, 8
1226 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D07945 Fenfluramine [4] 140, 144, 145, 149
1227 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D08456 Quetiapine [2] 6, 13
1228 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D08626 Trazodone [1] 2
1229 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D09645 Nelotanserin [1] 6
1230 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D09997 Cariprazine [1] 21
1231 HTR2B [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00270 Chlorpromazine [1] 254
1232 HTR2B [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00454 Olanzapine [2] 2, 8
1233 HTR2B [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00789 Chlorpromazine [1] 254
1234 HTR2B [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00820 Trazodone [1] 2
1235 HTR2B [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D03274 Chlorpromazine [1] 254
1236 HTR2B [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D04034 Chlorpromazine [1] 254
1237 HTR2B [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D06623 Olanzapine [2] 2, 8
1238 HTR2B [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D07945 Fenfluramine [4] 140, 144, 145, 149
1239 HTR2B [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D08626 Trazodone [1] 2
1240 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00270 Chlorpromazine [1] 254
1241 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00283 Clozapine [1] 6
1242 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00454 Olanzapine [2] 2, 8
1243 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00789 Chlorpromazine [1] 254
1244 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00820 Trazodone [1] 2
1245 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D02578 Agomelatine [1] 6
1246 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D03274 Chlorpromazine [1] 254
1247 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D04034 Chlorpromazine [1] 254
1248 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D06623 Olanzapine [2] 2, 8
1249 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D07945 Fenfluramine [4] 140, 144, 145, 149
1250 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D08626 Trazodone [1] 2
1251 HTR4 [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00274 Cisapride [1] 13
1252 HTR4 [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D02092 Cisapride [1] 13
1253 HTR4 [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D08236 Mosapride [1] 96
1254 HTR4 [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D09205 Prucalopride [3] 13, 51, 96
1255 HTR4 [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D09693 Velusetrag [1] 99
1256 HTR6 [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00454 Olanzapine [2] 2, 8
1257 HTR6 [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D06623 Olanzapine [2] 2, 8
1258 LEPR [2] Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease D05014 Metreleptin [1] 265
1259 MC1R [1] Neuroactive ligand-receptor interaction D10511 Afamelanotide [3] 159, 161, 254
1260 MC2R [1] Neuroactive ligand-receptor interaction D00146 Corticotropin [15] 2, 13, 14, 46, 49, 50, 66, 75, 78, 81, 84, 145, 193, 205, 222
1261 MC2R [1] Neuroactive ligand-receptor interaction D00284 Tetracosactide [5] 78, 83, 113, 145, 222
1262 MC4R [1] Neuroactive ligand-receptor interaction D11927 Setmelanotide [2] 202, 265
1263 MTNR1A [1] Neuroactive ligand-receptor interaction D02578 Agomelatine [1] 6
1264 MTNR1A [1] Neuroactive ligand-receptor interaction D02689 Ramelteon [3] 6, 8, 46
1265 MTNR1A [1] Neuroactive ligand-receptor interaction D08170 Melatonin [12] 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202
1266 MTNR1A [1] Neuroactive ligand-receptor interaction D09388 Tasimelteon [1] 202
1267 MTNR1B [1] Neuroactive ligand-receptor interaction D02578 Agomelatine [1] 6
1268 MTNR1B [1] Neuroactive ligand-receptor interaction D02689 Ramelteon [3] 6, 8, 46
1269 MTNR1B [1] Neuroactive ligand-receptor interaction D08170 Melatonin [12] 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202
1270 MTNR1B [1] Neuroactive ligand-receptor interaction D09388 Tasimelteon [1] 202
1271 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00729 Loperamide [2] 13, 97
1272 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00843 Nalbuphine [1] 85
1273 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D01340 Naloxone [2] 6, 226
1274 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02095 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
1275 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D03783 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
1276 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05111 Nalmefene [1] 6
1277 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05113 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
1278 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05312 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
1279 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05462 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
1280 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D07113 Loperamide [2] 13, 97
1281 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08144 Loperamide [2] 13, 97
1282 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08246 Nalbuphine [1] 85
1283 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08249 Naloxone [2] 6, 226
1284 OPRK1 [1] Neuroactive ligand-receptor interaction D00729 Loperamide [2] 13, 97
1285 OPRK1 [1] Neuroactive ligand-receptor interaction D00836 Buprenorphine [3] 46, 70, 298
1286 OPRK1 [1] Neuroactive ligand-receptor interaction D00843 Nalbuphine [1] 85
1287 OPRK1 [1] Neuroactive ligand-receptor interaction D01340 Naloxone [2] 6, 226
1288 OPRK1 [1] Neuroactive ligand-receptor interaction D02095 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
1289 OPRK1 [1] Neuroactive ligand-receptor interaction D03783 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
1290 OPRK1 [1] Neuroactive ligand-receptor interaction D05111 Nalmefene [1] 6
1291 OPRK1 [1] Neuroactive ligand-receptor interaction D05113 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
1292 OPRK1 [1] Neuroactive ligand-receptor interaction D05312 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
1293 OPRK1 [1] Neuroactive ligand-receptor interaction D05462 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
1294 OPRK1 [1] Neuroactive ligand-receptor interaction D07113 Loperamide [2] 13, 97
1295 OPRK1 [1] Neuroactive ligand-receptor interaction D07132 Buprenorphine [3] 46, 70, 298
1296 OPRK1 [1] Neuroactive ligand-receptor interaction D08144 Loperamide [2] 13, 97
1297 OPRK1 [1] Neuroactive ligand-receptor interaction D08246 Nalbuphine [1] 85
1298 OPRK1 [1] Neuroactive ligand-receptor interaction D08249 Naloxone [2] 6, 226
1299 OPRK1 [1] Neuroactive ligand-receptor interaction D08639 Trimebutine [1] 51
1300 OPRM1 [1] Neuroactive ligand-receptor interaction D00320 Fentanyl [4] 46, 70, 215, 231
1301 OPRM1 [1] Neuroactive ligand-receptor interaction D00729 Loperamide [2] 13, 97
1302 OPRM1 [1] Neuroactive ligand-receptor interaction D00836 Buprenorphine [3] 46, 70, 298
1303 OPRM1 [1] Neuroactive ligand-receptor interaction D00839 Hydromorphone [1] 70
1304 OPRM1 [1] Neuroactive ligand-receptor interaction D00842 Morphine [6] 36, 46, 70, 85, 86, 298
1305 OPRM1 [1] Neuroactive ligand-receptor interaction D00843 Nalbuphine [1] 85
1306 OPRM1 [1] Neuroactive ligand-receptor interaction D00845 Sufentanil [2] 70, 280
1307 OPRM1 [1] Neuroactive ligand-receptor interaction D01177 Remifentanil [2] 6, 70
1308 OPRM1 [1] Neuroactive ligand-receptor interaction D01340 Naloxone [2] 6, 226
1309 OPRM1 [1] Neuroactive ligand-receptor interaction D01355 Tramadol [5] 46, 70, 78, 226, 271
1310 OPRM1 [1] Neuroactive ligand-receptor interaction D01383 Meperidine [1] 298
1311 OPRM1 [1] Neuroactive ligand-receptor interaction D01399 Fentanyl [4] 46, 70, 215, 231
1312 OPRM1 [1] Neuroactive ligand-receptor interaction D01481 Dihydrocodeine [1] 310
1313 OPRM1 [1] Neuroactive ligand-receptor interaction D02095 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
1314 OPRM1 [1] Neuroactive ligand-receptor interaction D02271 Morphine [6] 36, 46, 70, 85, 86, 298
1315 OPRM1 [1] Neuroactive ligand-receptor interaction D03783 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
1316 OPRM1 [1] Neuroactive ligand-receptor interaction D05111 Nalmefene [1] 6
1317 OPRM1 [1] Neuroactive ligand-receptor interaction D05113 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
1318 OPRM1 [1] Neuroactive ligand-receptor interaction D05312 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
1319 OPRM1 [1] Neuroactive ligand-receptor interaction D05462 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
1320 OPRM1 [1] Neuroactive ligand-receptor interaction D05938 Sufentanil [2] 70, 280
1321 OPRM1 [1] Neuroactive ligand-receptor interaction D07113 Loperamide [2] 13, 97
1322 OPRM1 [1] Neuroactive ligand-receptor interaction D07132 Buprenorphine [3] 46, 70, 298
1323 OPRM1 [1] Neuroactive ligand-receptor interaction D07831 Dihydrocodeine [1] 310
1324 OPRM1 [1] Neuroactive ligand-receptor interaction D08047 Hydromorphone [1] 70
1325 OPRM1 [1] Neuroactive ligand-receptor interaction D08144 Loperamide [2] 13, 97
1326 OPRM1 [1] Neuroactive ligand-receptor interaction D08233 Morphine [6] 36, 46, 70, 85, 86, 298
1327 OPRM1 [1] Neuroactive ligand-receptor interaction D08246 Nalbuphine [1] 85
1328 OPRM1 [1] Neuroactive ligand-receptor interaction D08249 Naloxone [2] 6, 226
1329 OPRM1 [1] Neuroactive ligand-receptor interaction D08323 Oxymorphone [1] 70
1330 OPRM1 [1] Neuroactive ligand-receptor interaction D08343 Meperidine [1] 298
1331 OPRM1 [1] Neuroactive ligand-receptor interaction D08473 Remifentanil [2] 6, 70
1332 OPRM1 [1] Neuroactive ligand-receptor interaction D08623 Tramadol [5] 46, 70, 78, 226, 271
1333 OPRM1 [1] Neuroactive ligand-receptor interaction D08639 Trimebutine [1] 51
1334 OXTR [2] Neuroactive ligand-receptor interaction, Oxytocin signaling pathway D00089 Oxytocin [6] 6, 72, 127, 193, 206, 226
1335 OXTR [2] Neuroactive ligand-receptor interaction, Oxytocin signaling pathway D03008 Atosiban [1] 118
1336 OXTR [2] Neuroactive ligand-receptor interaction, Oxytocin signaling pathway D07229 Carbetocin [1] 193
1337 P2RX3 [2] Neuroactive ligand-receptor interaction, Taste transduction D11349 Gefapixant [2] 85, 226
1338 PLG [2] Neuroactive ligand-receptor interaction, Staphylococcus aureus infection D00160 Aminocaproic acid [1] 70
1339 PLG [2] Neuroactive ligand-receptor interaction, Staphylococcus aureus infection D01136 Tranexamic acid [6] 46, 70, 215, 227, 288, 299
1340 S1PR5 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10930 Etrasimod [3] 96, 97, 98
1341 S1PR5 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod [3] 13, 96, 97
1342 S1PR5 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11460 Siponimod [2] 13, 50
1343 AVPR1A [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00101 Vasopressin [1] 210
1344 AVPR1A [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D01236 Conivaptan [1] 86
1345 AVPR1A [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06672 Terlipressin [1] 299
1346 AVPR1A [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D07748 Conivaptan [1] 86
1347 AVPR1B [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00101 Vasopressin [1] 210
1348 AVPR1B [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06672 Terlipressin [1] 299
1349 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D00101 Vasopressin [1] 210
1350 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D00291 Desmopressin [6] 6, 64, 72, 75, 225, 288
1351 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D01213 Tolvaptan [3] 67, 72, 225
1352 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D01236 Conivaptan [1] 86
1353 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D02235 Desmopressin [6] 6, 64, 72, 75, 225, 288
1354 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D04752 Lixivaptan [1] 67
1355 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D06672 Terlipressin [1] 299
1356 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D07748 Conivaptan [1] 86
1357 CHRNA9 [1] Neuroactive ligand-receptor interaction D00765 Rocuronium [1] 296
1358 CHRNA9 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
1359 CHRNA9 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
1360 CHRNA9 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
1361 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
1362 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00267 Chlordiazepoxide [1] 46
1363 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
1364 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
1365 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [2] 36, 231
1366 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
1367 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
1368 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
1369 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00693 Chlordiazepoxide [1] 46
1370 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
1371 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
1372 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
1373 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
1374 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
1375 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01514 Etizolam [1] 46
1376 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
1377 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
1378 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
1379 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
1380 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
1381 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
1382 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
1383 PRL [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Prolactin signaling pathway D00780 Bromocriptine [2] 6, 74
1384 PRL [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Prolactin signaling pathway D00987 Cabergoline [3] 6, 74, 75
1385 PRL [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Prolactin signaling pathway D01348 Terguride [2] 51, 86
1386 PRL [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Prolactin signaling pathway D03165 Bromocriptine [2] 6, 74
1387 CHRNA10 [1] Neuroactive ligand-receptor interaction D00612 Trimethaphan [1] 17
1388 CHRNA10 [1] Neuroactive ligand-receptor interaction D00765 Rocuronium [1] 296
1389 CHRNA10 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
1390 CHRNA10 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
1391 CHRNA10 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
1392 PTAFR [2] Neuroactive ligand-receptor interaction, Staphylococcus aureus infection D07407 Rupatadine [1] 46
1393 PTGDR [1] Neuroactive ligand-receptor interaction D01128 Ramatroban [1] 13
1394 PTGER1 [2] Neuroactive ligand-receptor interaction, Pathways in cancer D00180 Alprostadil [2] 51, 70
1395 PTGER1 [2] Neuroactive ligand-receptor interaction, Pathways in cancer D02705 Alprostadil [2] 51, 70
1396 PTGER1 [2] Neuroactive ligand-receptor interaction, Pathways in cancer D02722 Limaprost [1] 70
1397 PTGER2 [3] Neuroactive ligand-receptor interaction, Renin secretion, Pathways in cancer D00419 Misoprostol [3] 46, 70, 271
1398 PTGER3 [3] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Pathways in cancer D00419 Misoprostol [3] 46, 70, 271
1399 PTGER4 [3] Neuroactive ligand-receptor interaction, Renin secretion, Pathways in cancer D00419 Misoprostol [3] 46, 70, 271
1400 PTGFR [2] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction D06274 Tafluprost [1] 299
1401 PTGFR [2] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction D08661 Unoprostone [1] 90
1402 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D00106 Epoprostenol [1] 86
1403 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D01337 Epoprostenol [1] 86
1404 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D01385 Ibudilast [2] 2, 13
1405 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D02720 Beraprost [1] 86
1406 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D02721 Iloprost [4] 51, 84, 85, 86
1407 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D06213 Treprostinil [6] 51, 84, 85, 86, 88, 210
1408 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D09994 Selexipag [6] 47, 51, 70, 84, 86, 88
1409 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D10725 Ralinepag [1] 86
1410 PTH1R [2] Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action D05364 Parathyroid hormone [4] 65, 70, 235, 326
1411 PTH1R [2] Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action D06078 Teriparatide [7] 46, 65, 68, 70, 71, 235, 274
1412 PTH2R [1] Neuroactive ligand-receptor interaction D05364 Parathyroid hormone [4] 65, 70, 235, 326
1413 HRH4 [1] Neuroactive ligand-receptor interaction D08040 Histamine [1] 13
1414 SSTR1 [1] Neuroactive ligand-receptor interaction D07431 Somatostatin [2] 67, 78
1415 SSTR1 [1] Neuroactive ligand-receptor interaction D10147 Pasireotide [3] 67, 74, 75
1416 SSTR2 [1] Neuroactive ligand-receptor interaction D00442 Octreotide [7] 67, 75, 84, 85, 89, 193, 227
1417 SSTR2 [1] Neuroactive ligand-receptor interaction D06495 Octreotide [7] 67, 75, 84, 85, 89, 193, 227
1418 SSTR2 [1] Neuroactive ligand-receptor interaction D07431 Somatostatin [2] 67, 78
1419 SSTR2 [1] Neuroactive ligand-receptor interaction D10147 Pasireotide [3] 67, 74, 75
1420 SSTR3 [1] Neuroactive ligand-receptor interaction D07431 Somatostatin [2] 67, 78
1421 SSTR3 [1] Neuroactive ligand-receptor interaction D10147 Pasireotide [3] 67, 74, 75
1422 SSTR4 [1] Neuroactive ligand-receptor interaction D07431 Somatostatin [2] 67, 78
1423 SSTR5 [1] Neuroactive ligand-receptor interaction D07431 Somatostatin [2] 67, 78
1424 SSTR5 [1] Neuroactive ligand-receptor interaction D10147 Pasireotide [3] 67, 74, 75
1425 TACR1 [1] Neuroactive ligand-receptor interaction D09378 Serlopitant [1] 36
1426 TBXA2R [2] Neuroactive ligand-receptor interaction, Platelet activation D01128 Ramatroban [1] 13
1427 TBXA2R [2] Neuroactive ligand-receptor interaction, Platelet activation D01896 Cilostazol [3] 51, 70, 124
1428 TBXA2R [2] Neuroactive ligand-receptor interaction, Platelet activation D04500 Ifetroban [3] 51, 86, 113
1429 THRA [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D01010 Levothyroxine [5] 19, 49, 78, 80, 222
1430 THRA [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D01011 Liothyronine [4] 13, 78, 210, 212
1431 THRA [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D07214 Tiratricol [2] 78, 139
1432 THRA [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D08125 Levothyroxine [5] 19, 49, 78, 80, 222
1433 THRA [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D08128 Liothyronine [4] 13, 78, 210, 212
1434 THRB [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D01010 Levothyroxine [5] 19, 49, 78, 80, 222
1435 THRB [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D01011 Liothyronine [4] 13, 78, 210, 212
1436 THRB [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D07214 Tiratricol [2] 78, 139
1437 THRB [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D08125 Levothyroxine [5] 19, 49, 78, 80, 222
1438 THRB [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D08128 Liothyronine [4] 13, 78, 210, 212
1439 THRB [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D09381 Sobetirome [1] 20
1440 C3 [9] Neuroactive ligand-receptor interaction, Phagosome, Neutrophil extracellular trap formation, Shigellosis, Pertussis, Staphylococcus aureus infection, Tuberculosis, Viral carcinogenesis, Systemic lupus erythematosus D11613 Pegcetacoplan [3] 2, 62, 222
1441 TRHR [1] Neuroactive ligand-receptor interaction D00176 Protirelin [1] 80
1442 C5 [6] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Prion disease, Pertussis, Staphylococcus aureus infection, Systemic lupus erythematosus D03940 Eculizumab [7] 11, 13, 14, 61, 62, 109, 222
1443 C5 [6] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Prion disease, Pertussis, Staphylococcus aureus infection, Systemic lupus erythematosus D11054 Ravulizumab [7] 2, 11, 13, 50, 62, 66, 109
1444 C5 [6] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Prion disease, Pertussis, Staphylococcus aureus infection, Systemic lupus erythematosus D11473 Nomacopan [3] 62, 109, 162
1445 C5 [6] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Prion disease, Pertussis, Staphylococcus aureus infection, Systemic lupus erythematosus D11477 Pozelimab [2] 11, 62
1446 C5 [6] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Prion disease, Pertussis, Staphylococcus aureus infection, Systemic lupus erythematosus D11696 Crovalimab [2] 62, 109
1447 C5 [6] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Prion disease, Pertussis, Staphylococcus aureus infection, Systemic lupus erythematosus D11838 Vilobelimab [3] 43, 44, 269
1448 C5AR1 [3] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Staphylococcus aureus infection D11093 Avacopan [3] 43, 44, 222
1449 TRPV1 [1] Neuroactive ligand-receptor interaction D00250 Capsaicin [5] 2, 6, 19, 86, 226
1450 CALCA [2] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D11055 Fremanezumab [2] 124, 226
1451 S1PR4 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10930 Etrasimod [3] 96, 97, 98
1452 S1PR4 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod [3] 13, 96, 97
1453 CHRNA6 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D00765 Rocuronium [1] 296
1454 CHRNA6 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D03365 Nicotine [3] 6, 13, 84
1455 CHRNA6 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D05156 Nicotine [3] 6, 13, 84
1456 CHRNA6 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D05157 Nicotine [3] 6, 13, 84
1457 S1PR2 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10930 Etrasimod [3] 96, 97, 98
1458 S1PR2 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod [3] 13, 96, 97
1459 GLP2R [1] Neuroactive ligand-receptor interaction D06053 Teduglutide [1] 96
1460 GABBR2 [2] Neuroactive ligand-receptor interaction, Taste transduction D00241 Baclofen [7] 2, 10, 13, 18, 65, 149, 206
1461 GABBR2 [2] Neuroactive ligand-receptor interaction, Taste transduction D08861 Arbaclofen Placarbil [1] 13
1462 GABBR2 [2] Neuroactive ligand-receptor interaction, Taste transduction D09791 Arbaclofen [2] 13, 206